Bristol-Myers says Celgene take over ‘best path’ for investors


U.S. drugmaker Bristol-Myers Squibb urged shareholders on Wednesday to support its planned takeover of Celgene Corp, as it faces opposition to the $74 billion deal from at least two prominent investors.